Organoid Models in Cancer Immunotherapy: Bioengineering Approach for Personalized Treatment DOI Creative Commons
Syarifah Tiara Noorintan,

Chelsie Angelius,

Fuad Gandhi Torizal

et al.

Immuno, Journal Year: 2024, Volume and Issue: 4(4), P. 312 - 324

Published: Sept. 27, 2024

Recent advances in organoid technology have revolutionized cancer biology and therapeutic interventions, offering personalized immunotherapy treatment. Organoids, three-dimensional cell cultures derived from patient tumors, accurately replicate the tumor microenvironment, providing unprecedented insights into tumor-immune interactions responses. In this literature-based study, we discuss various culture methods for diverse applications of organoids immunotherapy, including drug screening, treatment strategies, mechanistic studies. Additionally, address technological challenges associated with these propose potential future solutions to accelerate development novel immunotherapeutic approaches. This review highlights transformative models advancing preclinical modeling, evaluation, paving way more effective treatments.

Language: Английский

Advancing cancer research through organoid technology DOI Creative Commons
Zeng Ge, Yifan Yu, Meiting Wang

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: Nov. 8, 2024

The complexity of tumors and the challenges associated with treatment often stem from limitations existing models in accurately replicating authentic tumors. Recently, organoid technology has emerged as an innovative platform for tumor research. This bioengineering approach enables researchers to simulate, vitro, interactions between their microenvironment, thereby enhancing intricate interplay cells surroundings. Organoids also integrate multidimensional data, providing a novel paradigm understanding development progression while facilitating precision therapy. Furthermore, advancements imaging genetic editing techniques have significantly augmented potential organoids review explores application more precise simulations its specific contributions cancer research advancements. Additionally, we discuss evolving trends developing comprehensive utilizing technology.

Language: Английский

Citations

6
Organoid: Bridging the gap between basic research and clinical practice DOI
Guihu Weng, Jinxin Tao, Yueze Liu

et al.

Cancer Letters, Journal Year: 2023, Volume and Issue: 572, P. 216353 - 216353

Published: Aug. 18, 2023

Language: Английский

Citations

16
A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing DOI Creative Commons

Anton Lahusen,

Jierui Cai,

Reinhold Schirmbeck

et al.

Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)

Published: April 23, 2024

Abstract Poor treatment responses of pancreatic ductal adenocarcinoma (PDAC) are in large part due to tumor heterogeneity and an immunosuppressive desmoplastic stroma that impacts interactions with cells the microenvironment (TME). Thus, there is a pressing need for models probe contributions cellular noncellular crosstalk. Organoids promising model systems potential generate plethora data including phenotypic, transcriptomic genomic characterization but still require improvements culture conditions mimicking TME. Here, we describe INTERaction Organoid-in-MatriX ("InterOMaX") system, presents 3D co-culture-based platform investigating matrix-dependent We its uncover new molecular mechanisms T cell murine KPC ( LSL- Kras G12D /+27 /Trp53 tm1Tyj/J /p48 Cre/ + ) PDAC as well patient-derived organoids (PDOs). For this, customizable matrix homogenously sized organoid-in-matrix positioning cancer were designed based on standardized agarose microwell chip array system established co-culture inclusion stromal cells. detection orthogonal analysis human populations distinct sensitivity killing corroborated vivo . By enabling both identification validation gene candidates resistance, this sets stage better mechanistic understanding cell-intrinsic resistance phenotypes PDAC.

Language: Английский

Citations

5
Colorectal Cancer Immunotherapy: State of the Art and Future Directions DOI Creative Commons

Alyssa Mauri Cornista,

Maria Virginia Giolito, Kristi Baker

et al.

Gastro Hep Advances, Journal Year: 2023, Volume and Issue: 2(8), P. 1103 - 1119

Published: Jan. 1, 2023

Language: Английский

Citations

11
A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance DOI Creative Commons
Lei Sun,

Arabella Wan,

Shijia Yan

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2023, Volume and Issue: 14(1), P. 223 - 240

Published: Sept. 25, 2023

Lenvatinib, a second-generation multi-receptor tyrosine kinase inhibitor approved by the FDA for first-line treatment of advanced liver cancer, facing limitations due to drug resistance. Here, we applied multidimensional, high-throughput screening platform comprising patient-derived resistant tumor cells (PDCs), organoids (PDOs), and xenografts (PDXs) identify susceptibilities conquering lenvatinib resistance in clinically relevant settings. Expansion passaging PDCs PDOs from patient tumors retained functional fidelity treatment, expediting repurposing screens. Pharmacological identified romidepsin, YM155, apitolisib, NVP-TAE684 dasatinib as potential antitumor agents lenvatinib-resistant PDC PDO models. Notably, romidepsin enhanced response syngeneic mouse models triggering immunogenic cell death blocking EGFR signaling pathway. A combination immunotherapy achieved robust synergistic effects against humanized immunocompetent PDX Collectively, our findings suggest that cancer effectively recapitulate observed clinical settings expedite discovery providing feasible multidimensional personalized medicine.

Language: Английский

Citations

11
Advancing pancreatic cancer research and therapeutics: the transformative role of organoid technology DOI Creative Commons
Jihao Xu, Minh Duc Pham, Vincenzo Corbo

et al.

Experimental & Molecular Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 16, 2025

Research on pancreatic cancer has transformed with the advent of organoid technology, providing a better platform that closely mimics biology in vivo. This review highlights critical advancements facilitated by models understanding disease progression, evaluating therapeutic responses, and identifying biomarkers. These three-dimensional cultures enable proper recapitulation cellular architecture genetic makeup original tumors, insights into complex molecular dynamics at various stages ductal adenocarcinoma (PDAC). We explore applications organoids dissecting tumor microenvironment (TME); elucidating metastasis, drug resistance mechanisms; personalizing strategies. By overcoming limitations traditional 2D animal models, use significantly accelerated translational research, which is promising for improving diagnostic approaches clinical settings, ultimately aiming to improve outcomes patients cancer.

Language: Английский

Citations

0
Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients DOI Creative Commons
Xiongfei Xu, Shiwei Guo,

Haihui Gu

et al.

JCI Insight, Journal Year: 2025, Volume and Issue: 10(2)

Published: Jan. 22, 2025

T cells targeting a KRAS mutation can induce durable tumor regression in some patients with metastatic epithelial cancer. It is unknown whether mutant that are capable of killing be identified from peripheral blood pancreatic We developed an vitro stimulation approach and HLA-A*11:01-restricted G12V-reactive CD8+ HLA-DRB1*15:01-restricted CD4+ 2 out 6 HLA-A*11:01-positive cancer whose tumors expressed G12V. The cell receptor (TCR) was isolated validated to specifically recognize the G12V8-16 neoepitope. While engineered express this TCR recognized all 5 tested human HLA-A*11:01+ G12V+ organoids, recognition often modest, observed only organoids. IFN-γ priming organoids enhanced by TCR-engineered cells. could significantly slow growth established organoid-derived xenograft immunodeficient mice. Our data suggest has potential for use TCR-gene therapy, but additional strategies enhance likely will required increase clinical activity.

Language: Английский

Citations

0
Inhibition of Stemness and PD-L1 Expression by Pien Tze Huang Enhances T Cell-Mediated Killing of Colorectal Cancer DOI
Qin Lu, Zhuqing Zhang,

Sihan Liu

et al.

Journal of Ethnopharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 119447 - 119447

Published: Feb. 1, 2025

Language: Английский

Citations

0
The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates DOI Creative Commons

Liuyue Kan,

Yingyan Yu, Yan‐Jiang Wang

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: April 26, 2025

Gastric cancer (GC) is a prevalent digestive system tumor, the fifth most diagnosed worldwide, and leading cause of deaths. GC distinguished by its pronounced heterogeneity dynamically evolving tumor microenvironment (TME). The lack accurate disease models complicates understanding mechanisms impedes discovery novel drugs. A growing body evidence suggests that organoids, developed using organoid culture technology, preserve genetic, phenotypic, behavioral characteristics. organoids hold significant potential for predicting treatment responses in individual patients. This review provides comprehensive overview current clinical strategies GC, as well history, construction applications organoids. focus on role simulating TME to explore immune evasion intratumoral microbiota their guiding drug therapy facilitating screening. Furthermore, we summarize limitations underscore need continued technological advancements benefit both basic translational oncological research.

Language: Английский

Citations

0
High Content Imaging Applications of Advanced and Translational Disease Models in Drug Discovery and Development DOI
Weiyingqi Cui,

Mariam Haffa,

Francesco Massai

et al.

Royal Society of Chemistry eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 168 - 208

Published: April 30, 2025

There has been increasing interest in disease models with enhanced physiological fidelity. This led to the development of new methods for generating advanced utilizing primary cells and renewable sources, such as induced pluripotent stem organoids. Furthermore, combining these types high content imaging is expected positively impact all stages drug discovery pipeline. Since data rich assays can uncover nuanced cellular response perturbation. In this review, we focus on recent application models, covering general considerations cell source, culture format screening, preclinical studies translational applications, functional precision medicine approaches.

Language: Английский

Citations

0